Alkem Laboratories gets USFDA warning letter with OAI classification for Daman facility

Alkem Laboratories has received a warning letter from the USFDA for its manufacturing unit in Daman. The regulator issued an 'Official Action Indicated' (OAI) classification, which signals serious concerns about the facility's compliance with current Good Manufacturing Practices (cGMP). This classification indicates that the USFDA is taking a firm stance to ensure the facility addresses the identified issues immediately.
For investors, this news is significant as it highlights potential regulatory hurdles for Alkem's operations in the US market. The company has stated it will respond within the given timeframe and continues to supply approved products, but the OAI classification suggests deeper operational problems that could impact future approvals or inspections. The stock may face volatility as the market assesses the severity of the compliance issues and the company's ability to resolve them.
Excerpt from CNBC-TV18
Published On Nov 19, 2026 | 14:30 IST Last Updated On Nov 19, 2026 | 14:30 IST US drug regulators have issued an official warning following a plant inspection, prompting the drugmaker to implement corrective measures while maintaining ongoing supplies. Meanwhile, quarterly earnings showed revenue expanding despite a…Read the original at CNBC-TV18
Affected stocks
Bearish1 stockBull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Alkem Laboratories (ALKEM).
- Category: Company.
- AI reads the tone as negative (potentially bearish) for the stock.
Why it matters
A routine update for Alkem Laboratories. The tone is negative — watch for downside reaction. Use the price and stock snapshot to gauge how the market is responding.




